When Nureca Limited approached NPCS, they had a clear sense of direction — healthcare manufacturing — but needed help narrowing it down to something specific, technically grounded, and financially defensible. The medical device space is broad, competitive, and heavily regulated. Picking the wrong sub-sector can mean years of effort spent chasing a market that doesn't reward the investment.

After evaluating the client's investment profile and screening opportunities across healthcare sub-sectors, NPCS recommended an IV Cannulas Manufacturing Unit. IV cannulas are among the most fundamental consumables in any healthcare setting — every hospital, ICU, clinic, and government health facility uses them continuously. Because they're single-use by design, demand is recurring and entirely predictable. No seasonality, no trend dependency.

The broader market context adds further weight. India's healthcare infrastructure is expanding rapidly, government health spending is rising, and a meaningful share of medical consumables is still being imported — which means a quality-certified domestic manufacturer enters with both a cost advantage and policy support. Export potential to Southeast Asia, Africa, and the Middle East adds another growth dimension as the business scales.

On the technical side, we covered precision polymer extrusion, CNC needle grinding, clean-room assembly, optical quality inspection, sterilization systems, and automated packaging — laying out machinery selection, plant layout, and production parameters in full. The financial evaluation confirmed strong gross margins given low per-unit raw material costs and high institutional demand volumes, with a favorable payback horizon modeled in detail.

After reviewing the complete feasibility study, Nureca Limited confirmed their decision to move forward with implementation.